Healthcare / Drug Manufacturers - Specialty & GenericKSE
$16260.00
-690.00 (-4.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-11.0B · quality 43.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$89.2B
P/E
N/A
•EV/EBITDA
12.7x
↑ROE
-2.3%
↓Gross Margin
18.0%
↓Debt/Equity
1.14
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.9%
FCF CAGR
—
FCF margin
-6.8%
FCF / Net income
3.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $160.07B · net income $-2.89B · FCF $-10.96B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $160.07B | $160.07B | $171.76B | $160.35B | $156.04B |
| Net Income | $-2.89B | $-2.89B | $8.70B | $-24.19B | $-16.70B |
| EBITDA | $18.31B | $18.31B | $31.17B | $-1.63B | $2.29B |
| EPS | -526.00 | -526.00 | 1586.00 | -4410.00 | -3045.00 |
| Gross Margin | 18.0% | 18.0% | 20.9% | 5.0% | 10.8% |
| Operating Margin | 2.3% | 2.3% | 6.4% | -12.6% | -9.5% |
| Net Margin | -1.8% | -1.8% | 5.1% | -15.1% | -10.7% |
| Balance Sheet | |||||
| Debt/Equity | 1.14 | 1.14 | 1.00 | 1.19 | 0.94 |
| Current Ratio | 2.69 | 2.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.96B | $-10.96B | $9.75B | $-18.00B | $-10.43B |
| Returns | |||||
| ROE | -2.3% | -2.3% | 6.6% | -19.7% | -11.3% |
| Valuation | |||||
| P/E | — | — | 13.84 | — | — |
| EV/EBITDA | 12.72 | 12.72 | 8.04 | — | 116.77 |
| P/B | 0.70 | 0.70 | 0.92 | 1.05 | 0.90 |
| Growth & Yield | |||||
| Revenue Growth | -6.8% | -6.8% | 7.1% | 2.8% | — |
| EPS Growth | -133.2% | -133.2% | 136.0% | -44.8% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.1%
Start / end P/E
n/dx → n/dx
EPS bridge
1586.00 → -526.00
Residual
-26.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.